Evotec SE (EVO) Net Income towards Common Stockholders (2009 - 2025)
Evotec SE's (EVO) quarterly Net Income towards Common Stockholders came in at -$33.3 million in Q4 2025, up 60.83% year-over-year from -$20.7 million in Q4 2024, and up 33.56% quarter-over-quarter from -$50.1 million in Q3 2025.
Analysis
Evotec SE (EVO) Net Income towards Common Stockholders (2009 - 2025) Analysis & Trends
Evotec SE has disclosed Net Income towards Common Stockholders across 9 years of filings, most recently posting -$33.3 million for Q4 2025.
- In Q4 2025, Net Income towards Common Stockholders rose 60.83% year-over-year to -$33.3 million; the TTM figure through Dec 2025 stood at -$144.4 million (up 50.69% YoY), while the FY2025 annual figure was -$79.1 million, up 61.91% from the prior year.
- Net Income towards Common Stockholders came in at -$33.3 million for Q4 2025 at Evotec SE, up from -$50.1 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $158.3 million in Q3 2021 to a low of -$112.6 million in Q2 2024.
- Average Net Income towards Common Stockholders over 5 years is -$14.7 million, with a median of -$32.4 million recorded in 2025.
- The largest YoY upside for Net Income towards Common Stockholders was 9714.16% in 2021 against a maximum downside of 7140.17% in 2021.
- Over 5 years, Net Income towards Common Stockholders stood at -$36.0 million in 2021, then jumped by 177.07% to $27.8 million in 2022, then tumbled by 223.75% to -$34.3 million in 2023, then sank by 147.3% to -$84.9 million in 2024, then surged by 60.83% to -$33.3 million in 2025.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$33.3 million in Q4 2025, -$50.1 million in Q3 2025, and -$31.4 million in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.06 Bn | 42.11 Bn | 1.44 Bn | 241.00 Mn |
| 2 | Medpace Holdings | 16.50 Bn | 16.00 Bn | 201.64 Mn | 121.36 Mn |
| 3 | Charles River Laboratories International | 13.77 Bn | 13.62 Bn | 452.07 Mn | -760,000.00 |
| 4 | Icon | 12.62 Bn | 11.69 Bn | 479.29 Mn | 198.40 Mn |
| 5 | Fortrea Holdings | 1.68 Bn | 1.51 Bn | 139.20 Mn | -13.20 Mn |
| 6 | Evotec SE | 661.34 Mn | 235.46 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 442.79 Mn | 358.26 Mn | 18.44 Mn | -46.71 Mn |
| 8 | Champions Oncology | 72.49 Mn | 72.62 Mn | 7.03 Mn | -667,000.00 |
| 9 | MindWalk Holdings | 61.66 Mn | 53.38 Mn | 1.82 Mn | -2.50 Mn |
| 10 | VivoSim Labs | 1.47 Mn | 1.47 Mn | - | -2.74 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -33.27 Mn |
| Sep 30, 2025 | -50.07 Mn |
| Jun 30, 2025 | -31.44 Mn |
| Mar 31, 2025 | -29.58 Mn |
| Dec 31, 2024 | -84.93 Mn |
| Sep 30, 2024 | -59.43 Mn |
| Jun 30, 2024 | -112.65 Mn |
| Mar 31, 2024 | -35.73 Mn |
| Dec 31, 2023 | -34.34 Mn |
| Jun 30, 2023 | -13.89 Mn |
| Dec 31, 2022 | 27.75 Mn |
| Sep 30, 2022 | 47.67 Mn |
| Jun 30, 2022 | -29.81 Mn |
| Mar 31, 2022 | -82.20 Mn |
| Dec 31, 2021 | -36.01 Mn |
| Sep 30, 2021 | 158.34 Mn |
| Jun 30, 2021 | 72.27 Mn |
| Mar 31, 2021 | 63.57 Mn |
| Dec 31, 2020 | 511,492.35 |
| Sep 30, 2020 | -1.65 Mn |